In this third article in the series, we talk with Philip Seo, MD, MHS, about eosinophilic granulomatosis with polyangiitis (EGPA).
Search results for: etanercept
20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
Treatment Factors to Consider in Patients with JIA
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.
Insight into the Biosimilar Prescribing Habits of Rheumatologists
The use of biosimilar treatments is increasing, according to surveys conducted in 2018 and 2020 of rheumatologists from eight countries. In the two-year period, Japan had the largest increase in biosimilar prescriptions, with only 6% of surveyed rheumatologists reporting they prefer prescribing originator biologic agents.
ACR Leads AMA Resolution on Payer Financial Incentives to Patients to Switch Treatment
Spurred by a recent Cigna policy, the ACR will lead a resolution to oppose insurance companies providing financial incentives for patients to switch treatments. Several specialties are cosponsoring the resolution for a special meeting of the AMA House of Delegates in June.
Cigna Offers Patients Financial Incentive to Switch Treatments
The ACR has sent a letter to Cigna expressing opposition to the initiative, which jeopardizes patients’ health, interferes with medical decision making, undermines the doctor-patient relationship and may disproportionately affect patients of lower socioeconomic status.
14 Rheumatology Treatments Make Top 50 List of Drugs That Can Cause Anaphylaxis
A recent study of data from the FDA’s Adverse Event Reporting System reveals that 14 drugs commonly prescribed by rheumatologists are on the list of the top 50 drugs that can cause anaphylaxis.
Study Examines Tofacitinib’s Long-Term Cardiovascular Risk & More
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
Case Report: A Non-Tuberculous Mycobacterial Infection
Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection. Many biologic agents, particularly…
Biologics in Rheumatology: Revolution & Perspectives
A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 30
- Next Page »